Introduction
Add App Processing Pathway Flowchart Diagram is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Amyloid Precursor Protein (APP) is a type-I transmembrane protein that can be processed through alternative proteolytic pathways, producing fragments with different biological consequences.1Safety and efficacy of crenezumab in cognitively unimpaired (2026)Open reference2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference In Alzheimer’s Disease, APP processing is central because sequential cleavage by beta-secretase and gamma-secretase generates Amyloid-Beta peptides that accumulate into toxic oligomers and plaques.[^4][^5]4'Haass and Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer''s Amyloid-Beta-peptide (2007)'Open reference 2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference
APP is broadly expressed in the central nervous system, especially in neurons, and participates in synaptic development, axonal transport, and cell-cell signaling. The disease relevance of APP comes from how strongly its proteolytic fate determines Aβ generation, peptide length distribution (especially Aβ42), and downstream neuroinflammatory and synaptotoxic responses.2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference5Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (2001)Open reference 3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference
Molecular Processing Pathways
Non-amyloidogenic pathway
In the non-amyloidogenic route, APP is first cleaved by alpha-secretase within the Aβ region, preventing intact Aβ peptide formation.6Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease (1999)Open reference This generates soluble APP-alpha (sAPPα), generally associated with neurotrophic and synaptic-supportive effects, plus a membrane C-terminal fragment that is later processed by gamma-secretase into smaller non-amyloidogenic peptides.2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference02Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference1 [^4]
This pathway is often considered protective in AD biology because it competes directly with beta-secretase access to APP. Shifting APP processing toward alpha-secretase cleavage reduces amyloidogenic substrate availability and can lower total Aβ burden in experimental systems.2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference22Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference3 [^5]
Amyloidogenic pathway
In the amyloidogenic route, beta-secretase (BACE1) cleaves APP to release soluble APP-beta (sAPPβ) and a membrane-bound C99 fragment.[^4][^5] Gamma-secretase then processes C99 in endosomal and trans-Golgi related compartments to produce Aβ peptides of varying length, including aggregation-prone Aβ42.2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference42Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference5 2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference6
The relative proportions of Aβ40 versus Aβ42 are influenced by gamma-secretase processivity, APP trafficking, and pathogenic variants in APP or PSEN1/PSEN2. Increased production of longer Aβ species, or reduced clearance, is strongly linked to earlier and more severe amyloid pathology.2Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference72Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference82Amyloid-related imaging abnormalities in Alzheimer's disease (2024)Open reference9 3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference0
Cellular Context And Disease Mechanisms
APP processing is tightly coupled to membrane trafficking. APP internalization into endosomes increases its exposure to BACE1 and favors amyloidogenic cleavage, while altered recycling and lysosomal flux can amplify Aβ production over time.3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference1[^4] Lipid microdomains, synaptic activity, and inflammation-related signaling also reshape secretase localization and activity, which helps explain why Aβ biology differs across cell types and disease stages.3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference23Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference3 3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference4
Aβ oligomers produced downstream of APP processing can impair synaptic transmission, trigger glial activation, and interact with tau-related degeneration pathways. These interactions place APP processing upstream of multiple AD pathophysiology nodes rather than in an isolated amyloid-only cascade.3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference53Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference6 3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference7
Therapeutic Targeting Of APP Processing
Therapeutic strategies have focused on reducing amyloidogenic APP cleavage or altering Aβ product profiles. BACE inhibition was a major clinical strategy based on strong target biology and preclinical Aβ reduction, but large trials in prodromal AD (for example verubecestat) failed to show clinical benefit and raised tolerability concerns, highlighting complexity around intervention timing and target engagement in humans.3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference8 3Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)Open reference9
Gamma-secretase modulation has also been explored, including compounds that selectively lower Aβ42 without fully blocking essential substrate processing. Earlier small-molecule work established pharmacologic feasibility for shifting Aβ output, but translation remains constrained by safety and off-target pathway effects.4'Haass and Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer''s Amyloid-Beta-peptide (2007)'Open reference0 4'Haass and Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer''s Amyloid-Beta-peptide (2007)'Open reference1
Current translational emphasis is increasingly stage-specific: combining biomarker-guided patient selection, earlier intervention windows, and multi-pathway treatment strategies that pair amyloid lowering with neuroinflammation and synaptic resilience approaches. 4'Haass and Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer''s Amyloid-Beta-peptide (2007)'Open reference2
See Also
-
APP (Amyloid Precursor Protein)
External Links
Background
The study of Add App Processing Pathway Flowchart Diagram has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research Updates (2024-2026)
Recent advances in this mechanism have revealed new insights into neurodegenerative disease pathogenesis and therapeutic targets.
Key Recent Findings
-
Selkoe et al., Safety and efficacy of crenezumab in cognitively unimpaired (2026)
-
Selkoe et al., Amyloid-related imaging abnormalities in Alzheimer’s disease (2024)
-
Hardy et al., Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)
Allen Brain Atlas Resources
-
Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions
-
Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy
-
Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury
-
BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data
References
- Safety and efficacy of crenezumab in cognitively unimpaired (2026)
- Amyloid-related imaging abnormalities in Alzheimer's disease (2024)
- Heterozygous TREM2 and PSEN1 mutations in early-onset AD (2025)
- 'Haass and Selkoe, Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer''s Amyloid-Beta-peptide (2007)'
- Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (2001)
- Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease (1999)
- Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein (1998)
- Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases (2000)
- NSAIDs reduce Aβ42 production by modulating gamma-secretase (2001)
- Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease (2019)
Sister wikis (recently updated · no domain on this page)
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- Agent Recipe: AI-for-Biology Closed-Loop with Reviewer Handoffs and Eval Contracts
- test
- JGBO-I27: Top 10 GBO Questions for Prioritization
- JGBO-I27: Top 10 GBO Questions for Prioritization
- Design Brief: Beta-test Evaluation Protocol for SciDEX v2 Design Trajectories
- Andy — Showcase Findings (auto-curated)
- Kris — Showcase Findings (auto-curated)
Recent activity here
No recent events touching this page.